His primary areas of study are Alzheimer's disease, Internal medicine, Disease, Dementia and Clinical trial. The various areas that Paul S. Aisen examines in his Alzheimer's disease study include Biomarker, Neuroimaging and Degenerative disease. His Internal medicine research is multidisciplinary, incorporating perspectives in Placebo, Oncology and Endocrinology.
His biological study spans a wide range of topics, including Gerontology, Bioinformatics, Intensive care medicine, Pathophysiology and Neuroscience. His Dementia study combines topics in areas such as Meta-analysis, Psychiatry, Central nervous system disease and Pediatrics. As a part of the same scientific family, he mostly works in the field of Alzheimer's Disease Neuroimaging Initiative, focusing on Alzheimer's disease biomarkers and, on occasion, Senile plaques and Neurodegeneration.
Disease, Alzheimer's disease, Internal medicine, Clinical trial and Dementia are his primary areas of study. His studies in Disease integrate themes in fields like Gerontology, Neuroimaging, Cognition, Neuroscience and Biomarker. His Cognition research includes elements of Cohort and Clinical psychology.
Specifically, his work in Alzheimer's disease is concerned with the study of Alzheimer's Disease Neuroimaging Initiative. Paul S. Aisen has researched Internal medicine in several fields, including Placebo, Oncology and Endocrinology. His Clinical trial research integrates issues from Physical medicine and rehabilitation, Drug development, Intensive care medicine, Physical therapy and Neurology.
Paul S. Aisen mostly deals with Disease, Clinical trial, Internal medicine, Cognition and Dementia. His Disease study incorporates themes from Neurology, Drug development, Asymptomatic and Intensive care medicine. The concepts of his Clinical trial study are interwoven with issues in Biomarker, Geriatrics gerontology, Physical medicine and rehabilitation and Observational study.
His Internal medicine study integrates concerns from other disciplines, such as Placebo and Oncology. His Dementia research incorporates elements of Randomized controlled trial, Neuroscience, Verubecestat and Pediatrics. Paul S. Aisen has included themes like MEDLINE and Cognitive test in his Alzheimer's disease study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling;Paul S. Aisen;Laurel A. Beckett;David A. Bennett.
Alzheimers & Dementia (2011)
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Clifford R Jack;David S Knopman;William J Jagust;Leslie M Shaw.
Lancet Neurology (2010)
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.
Clifford R Jack;David S Knopman;William J Jagust;Ronald C Petersen.
Lancet Neurology (2013)
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease
Randall J. Bateman;Chengjie Xiong;Tammie L.S. Benzinger;Anne M. Fagan.
The New England Journal of Medicine (2012)
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Leslie M. Shaw;Hugo Vanderstichele;Malgorzata Knapik-Czajka;Christopher M. Clark.
Annals of Neurology (2009)
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
RS Rachelle S. Doody;RG Ronald G. Rg Thomas;Martin Farlow;Takeshi Iwatsubo.
The New England Journal of Medicine (2014)
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
Michael W. Weiner;Michael W. Weiner;Dallas P. Veitch;Paul S. Aisen;Laurel A Beckett.
Alzheimers & Dementia (2012)
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Bruno Dubois;Harald Hampel;Harald Hampel;Howard H. Feldman;Philip Scheltens.
Alzheimers & Dementia (2016)
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.
R. C. Petersen;P. S. Aisen;Laurel A Beckett;M. C. Donohue.
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.
Michael Grundman;Ronald C. Petersen;Steven H. Ferris;Ronald G. Thomas.
JAMA Neurology (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: